RxDoctor Payments Data

Terry Wells, MD

Family Medicine · Lufkin, TXNPI 1639104813

Payments from drug & device makers

$407,462in general payments, 2019–2025

Across 99 payments — averaging $4115.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$325K
  • AstraZeneca$34K
  • American Regent$25K
  • Merck$12K
  • Teva Pharmaceuticals USA, Inc.$11K
  • Ascensia Diabetes Care US Inc.$159
  • plus $830 from 17 others

What the payments were for

  • Food & beverage$96986%
  • Education$15914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$407,462 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$62,827
Medicare patients
133
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol87$61,278
OzempicSemaglutide50$48,679
RybelsusSemaglutide28$44,919
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,393
TradjentaLinagliptin41$20,209
JardianceEmpagliflozin15$16,130
Trijardy XrEmpaglifloz/Linaglip/Metformin18$13,200
MyrbetriqMirabegron17$10,948
Tresiba Flextouch U-100Insulin Degludec14$7,234
SynthroidLevothyroxine Sodium53$3,384
Valsartan124$3,199
Raloxifene Hcl40$2,919
Gabapentin237$2,852
Pregabalin44$2,307
Tizanidine Hcl63$2,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$95$93,59978 claims
AstraZenecaFarxiga$33,629$61,27887 claims
Boehringer IngelheimTradjenta, Jardiance, Trijardy Xr$97$49,53974 claims
GSKTrelegy Ellipta$94$35,39339 claims
AbbVieSynthroid$63$3,38453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →